Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. (not Canton Strategic Holdings, Inc.) on June 18, 2024. The filing reports the entry into a Material Definitive Agreement regarding a private placement of securities. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Bridgewater, NJ.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction with the following financial parameters:
- Gross Proceeds: Approximately $2.08 million (before fees and expenses).
- Securities Issued:
- 207,292 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 452,253 shares at $0.001 per share.
- Common Warrants to purchase up to 329,771 shares at $3.09 per share.
- Purchase Price: $3.16 per share of Common Stock (or common stock equivalent).
- Use of Proceeds: Clinical development and working capital, specifically supporting the TH104 development program.
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes and Transaction Terms
The primary material change is the execution of a Securities Purchase Agreement with institutional investors. Key terms include:
- Closing Date: Expected on June 21, 2024, subject to customary conditions.
- Warrant Terms: Common Warrants are exercisable six months post-issuance with a 5.5-year term. Pre-Funded Warrants are immediately exercisable.
- Ownership Limitations: Holders cannot exercise warrants if it results in ownership exceeding 4.99% (or 9.99% at the holder's election) of outstanding common stock.
- Placement Agent: President Street Global served as the exclusive placement agent.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance the company's clinical development pipeline, specifically the TH104 program. The filing notes that the closing is subject to customary conditions. No specific forward-looking financial guidance, risk factors, or contingencies beyond the standard closing conditions were detailed in this specific text excerpt.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Confirm the exact number of shares issued upon the exercise of Pre-Funded Warrants, as these are often exercised immediately.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the progress of the TH104 development program to assess the utilization of the raised capital.
- Check subsequent filings for any dilution impact on existing shareholders due to the warrant exercises.